Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Cited by (122)

Items 101–122 of 122

1. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
   Song, Ge, He, Wan-ting, Callaghan, Sean, Anzanello, Fabio, Huang, Deli, Ricketts, James, Torres, Jonathan L., Beutler, Nathan, Peng, Linghang, Vargas, Sirena et al. · 2020
2. Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns
   Baumgarth, Nicole, Nikolich-Žugich, Janko, Lee, F Eun-Hyung, Bhattacharya, Deepta · 2020 · The Journal of Immunology
3. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
   Voigt, Emily A., Gerhardt, Alana, Hanson, Derek, Jennewein, Madeleine F., Battisti, Peter, Reed, Sierra, Singh, Jasneet, Mohamath, Raodoh, Bakken, Julie, Beaver, Samuel et al. · 2022 · npj Vaccines
4. Discrete SARS-CoV-2 antibody titers track with functional humoral stability
   Bartsch, Yannic C., Fischinger, Stephanie, Siddiqui, Sameed M., Chen, Zhilin, Yu, Jingyou, Gebre, Makda, Atyeo, Caroline, Gorman, Matthew J., Zhu, Alex Lee, Kang, Jaewon et al. · 2021 · Nature Communications
5. T cells in COVID-19 — united in diversity
   Swadling, Leo, Maini, Mala K. · 2020 · Nature Immunology
6. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
   Ayoub, Houssein H, Chemaitelly, Hiam, Seedat, Shaheen, Makhoul, Monia, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A, Coyle, Peter, Jeremijenko, Andrew et al. · 2021 · Journal of Global Health
7. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2
   Woldemeskel, Bezawit A., Kwaa, Abena K., Garliss, Caroline C., Laeyendecker, Oliver, Ray, Stuart C., Blankson, Joel N. · 2020 · Journal of Clinical Investigation
8. Multifunctional role of exosomes in viral diseases: From transmission to diagnosis and therapy
   Chaudhari, Pinal, Ghate, Vivek, Nampoothiri, Madhavan, Lewis, Shaila · 2022 · Cellular Signalling
9. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
   Seedat, Shaheen, Chemaitelly, Hiam, Ayoub, Houssein H., Makhoul, Monia, Mumtaz, Ghina R., Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A., Coyle, Peter et al. · 2021 · Scientific Reports
10. Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients
    Duan, Ya-qi, Xia, Ming-hui, Ren, Liang, Zhang, Yan-fang, Ao, Qi-lin, Xu, San-peng, Kuang, Dong, Liu, Qian, Yan, Bing, Zhou, Yi-wu et al. · 2020 · Current Medical Science
11. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities
    Yaqinuddin, Ahmed · 2020 · Medical Hypotheses
12. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults
    Palmer, Christine D., Scallan, Ciaran D., Kraemer Tardif, Lauren D., Kachura, Melissa A., Rappaport, Amy R., Koralek, Daniel O., Uriel, Alison, Gitlin, Leonid, Klein, Joshua, Davis, Matthew J. et al. · 2023 · Nature Communications
13. Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
    Cho, Alice, Muecksch, Frauke, Schaefer-Babajew, Dennis, Wang, Zijun, Finkin, Shlomo, Gaebler, Christian, Ramos, Victor, Cipolla, Melissa, Mendoza, Pilar, Agudelo, Marianna et al. · 2021
14. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera
    Steffen, Tara L., Stone, E. Taylor, Hassert, Mariah, Geerling, Elizabeth, Grimberg, Brian T., Espino, Ana M., Pantoja, Petraleigh, Climent, Consuelo, Hoft, Daniel F., George, Sarah L. et al. · 2020
15. Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
    Pratama, Nando Reza, Wafa, Ifan Ali, Budi, David Setyo, Sutanto, Henry, Asmarawati, Tri Pudy, Barlian Effendi, Gema, Wungu, Citrawati Dyah Kencono · 2022 · Vaccines
16. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
    Lederer, Katlyn, Parvathaneni, Kalpana, Painter, Mark M., Bettini, Emily, Agarwal, Divyansh, Lundgreen, Kendall A., Weirick, Madison, Goel, Rishi R., Xu, Xiaoming, Drapeau, Elizabeth M. et al. · 2021
17. Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19
    Jensen, Melanie Peta, George, Marc, Gilroy, Derek, Sofat, Reecha · 2021 · British Journal of Clinical Pharmacology
18. Molecular epidemiology of SARS CoV-2: a review of current data on genetic variability of the virus
    Parczewski, Miłosz, Ciechanowicz, Andrzej · 2020 · Polish Archives of Internal Medicine
19. IgV somatic mutation of human anti–SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity
    de Mattos Barbosa, Mayara Garcia, Liu, Hui, Huynh, Daniel, Shelley, Greg, Keller, Evan T., Emmer, Brian T., Sherman, Emily, Ginsburg, David, Kennedy, Andrew A., Tai, Andrew W. et al. · 2021 · JCI Insight
20. Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine
    Wadapurkar, Rucha, Singh, Sanjay, Singh, Ajay · 2024 · Vaccine
21. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
    Piccoli, Luca, Park, Young-Jun, Tortorici, M. Alejandra, Czudnochowski, Nadine, Walls, Alexandra C., Beltramello, Martina, Silacci-Fregni, Chiara, Pinto, Dora, Rosen, Laura E., Bowen, John E. et al. · 2020 · Cell
22. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
    Cele, Sandile, Gazy, Inbal, Jackson, Laurelle, Hwa, Shi-Hsia, Tegally, Houriiyah, Lustig, Gila, Giandhari, Jennifer, Pillay, Sureshnee, Wilkinson, Eduan, Naidoo, Yeshnee et al. · 2021